165423 History and politics of regulating harm: Tobacco, lead, and Bisphenol A

Tuesday, November 6, 2007: 5:30 PM

Allan M. Brandt, PhD , Department of the History of Science, Harvard University, Cambridge, MA
Gerald Markowitz, PhD , History/Thematic Studies, John Jay College, New York, NY
Sarah A. Vogel, MPH, MEM , Center for the History and Ethics of Public Health, Columbia University, New York, NY
We are increasingly aware of environmental threats to health, including the threats posed by hazardous commercial products. In this panel we trace the history of the debates about the safety of tobacco, lead-based paint products, and Bisphenol A, an important component of plastics. In each of the cases that the panel will explore, industry fought regulation, engaging in a multi-pronged attack on public health and science while launching appeals to the public that touted the products' safety. This panel uses the history of struggle over three very different products to underscore the role of politics in the regulation and amelioration of exposure to hazardous commercial products. The rich histories of how risk was constructed and scientific evidence marshaled by players both inside and outside of industry are central to understanding ongoing debates and legal challenges about who must be held accountable for harms and how these industries can be regulated.

Learning Objectives:
1. Recognize the role of politics in the regulation and amelioration of exposure to hazardous commercial products. 2. Apply a historical framework to the analysis of contemporary policy regarding the regulation and amelioration of hazardous commercial products. 3. Assess the construction of risk in the hands of industry and public health. 4. Assess the use of scientific evidence by industry and public health.

Keywords: History, Policy/Policy Development

Presenting author's disclosure statement:

Any relevant financial relationships? No
Any institutionally-contracted trials related to this submission?

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.